Corteva, Inc. (CTVA) reported $3.98 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 7.3%. EPS of $0.32 for the same period compares to $0.15 a year ago.
The reported revenue represents a surprise of +0.80% over the Zacks Consensus Estimate of $3.95 billion. With the consensus EPS estimate being $0.34, the EPS surprise was -5.88%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Corteva, Inc. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Seed: $1.77 billion versus the four-analyst average estimate of $1.70 billion. The reported number represents a year-over-year change of +8.4%.
- Revenue- Crop Protection: $2.21 billion versus the four-analyst average estimate of $2.23 billion. The reported number represents a year-over-year change of +6.5%.
- Revenue- Crop Protection- Other: $196 million versus the two-analyst average estimate of $355.65 million. The reported number represents a year-over-year change of -46.2%.
- Revenue- Seed- Other: $120 million versus $127.79 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +8.1% change.
- Revenue- Crop Protection- Herbicides: $1.03 billion versus the two-analyst average estimate of $1.04 billion. The reported number represents a year-over-year change of +4%.
- Revenue- Crop Protection- Insecticides: $490 million versus $505.04 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +10.9% change.
- Revenue- Crop Protection- Fungicides: $320 million compared to the $303.56 million average estimate based on two analysts. The reported number represents a change of +16.4% year over year.
- Revenue- Seed- Soybean: $154 million compared to the $146.91 million average estimate based on two analysts. The reported number represents a change of +6.2% year over year.
- Revenue- Seed- Corn: $1.41 billion versus $1.50 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +7.9% change.
- Revenue- Seed- Other oilseeds: $87 million versus $74.40 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +22.5% change.
- Operating EBITDA- Seed: $93 million compared to the $171.84 million average estimate based on four analysts.
- Operating EBITDA- Corporate: -$29 million versus the four-analyst average estimate of -$25.91 million.
View all Key Company Metrics for Corteva, Inc. here>>>
Shares of Corteva, Inc. have returned +15.2% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Corteva, Inc. (CTVA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.